Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
LaFleur Minerals Acquires McKenzie East Gold Project Expanding Val-d'Or Gold Portfolio; Advances Aggressive Drilling at Swanson Gold Project
SAGA Metals Reports Assays from R-0027 to R-0029 with Intercepts Including 53.02% Fe2O3, 6.46% TiO2, 0.441% V2O5 from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
